Blue Trust’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$84 Buy
+7
New +$88 ﹤0.01% 2433
2025
Q4
– Sell
-10
Closed -$173 – 2667
2025
Q3
$173 Hold
10
– – ﹤0.01% 2518
2025
Q2
$94 Sell
10
-53
-84% -$435 ﹤0.01% 2406
2025
Q1
$448 Buy
63
+53
+530% +$535 ﹤0.01% 2368
2024
Q4
$117 Sell
10
-4,179
-100% -$65.2K ﹤0.01% 2399
2024
Q3
$93.8K Buy
4,189
+2,707
+183% +$62.4K ﹤0.01% 1254
2024
Q2
$40.8K Buy
1,482
+1,398
+1,664% +$33.3K ﹤0.01% 1332
2024
Q1
$2.31K Sell
84
-735
-90% -$20.4K ﹤0.01% 1796
2023
Q4
$26K Buy
+819
New +$23.5K ﹤0.01% 1188
2023
Q2
– Sell
-23
Closed -$1K – 2365
2023
Q1
$1K Sell
23
-88
-79% -$3.45K ﹤0.01% 2183
2022
Q4
$6K Buy
111
+96
+640% +$4.56K ﹤0.01% 1681
2022
Q3
$1K Buy
+15
New +$931 ﹤0.01% 1969

Other funds holding NTLA

Blue Trust's NTLA Position: Q3 2026 in Review

Blue Trust opened a new position in Intellia Therapeutics (NTLA) in Q3 2026: 7 shares worth $84. The stake represents ﹤0.01% of the portfolio and ranks #2433 among its holdings. This is a return to the name: Blue Trust previously reported a position in NTLA as recently as Q3 2025.

Blue Trust first reported a position in NTLA in Q3 2022 and has held it in 12 quarters since. The position peaked at $93.8K in Q3 2024. 244 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Blue Trust held 7 shares of Intellia Therapeutics worth $84 as of Q3 2026.
  • Intellia Therapeutics was a new Blue Trust position in Q3 2026.
  • Intellia Therapeutics made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #2433 holding.
  • Blue Trust first reported a position in Intellia Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • Blue Trust's Intellia Therapeutics position peaked at $93.8K in Q3 2024.
  • 244 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.